TNFRSF8 and mature T-cell and NK-cell non-Hodgkin lymphoma: An ongoing phase II trial is being conducted to provide additional data on retreatment with brentuximab vedotin for patients with classical Hodgkin lymphoma, sALCL, or other CD30-positive PTCL (NCT03947255).35